Immune checkpoint inhibitors in gynecologic cancers with lessons learned from non-gynecologic cancers

Expert Opinion on Biological Therapy

Volumn 16, Issue 8, 2016, Pages 989-1004

  Menderes, Gulden ^a   Hicks, Christopher ^b   Black, Jonathan D ^a   Schwab, Carlton L ^a   Santin, Alessandro D ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BRIDGEPORT HOSPITAL   (United States)

Author keywords

anti cytotoxic T lymphocytes; anti program death ligands; anti programmed death agents; checkpoint inhibition; gynecologic cancer; Immunotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DEATH RECEPTOR; IMMUNE CHECKPOINT INHIBITOR; IMMUNOMODULATING AGENT; PROGRAMMED DEATH 1 RECEPTOR; PROGRAMMED DEATH RECEPTOR 1 LIGAND; UNCLASSIFIED DRUG; CTLA4 PROTEIN, HUMAN;

ADRENAL DISEASE; ADVANCED CANCER; ANOREXIA; ARTHRALGIA; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL (TOPIC); COLITIS; DIARRHEA; DRUG FATALITY; DRUG MECHANISM; DRUG SAFETY; FATIGUE; FEMALE GENITAL TRACT CANCER; HEADACHE; HUMAN; HYPOPHYSIS DISEASE; IMMUNE RESPONSE; IMMUNOPATHOLOGY; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY (TOPIC); NAUSEA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRECLINICAL STUDY; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; T LYMPHOCYTE ACTIVATION; THYROID DISEASE; TUMOR MICROENVIRONMENT; VOMITING; ADVERSE EFFECTS; FEMALE; GENITAL NEOPLASMS, FEMALE; IMMUNOLOGY; IMMUNOTHERAPY; TUMOR RECURRENCE;

CTLA-4 ANTIGEN; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; IMMUNOTHERAPY; NEOPLASM RECURRENCE, LOCAL; TUMOR MICROENVIRONMENT;

EID: 84964425439     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1080/14712598.2016.1177018     Document Type: Review

References (120)

1. J.Couzin-Frankel Breakthrough of the year 2013. Cancer immunotherapy. Science. 2013;342:1432–1433. doi:10.1126/science.342.6165.1432.
2. D.L.Porter, B.L.Levine, M.Kalos, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365:725–733.
3. S.L.Topalian, F.S.Hodi, J.R.Brahmer, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–2454. doi:10.1056/NEJMoa1200690.•• Landmark study demonstrating that blockade of programmed death 1 (PD-1), an inhibitory receptor expressed by T-cells, can overcome immune resistance.
4. J.R.Brahmer, S.S.Tykodi, L.Q.Chow, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455–2465.•• Important study reporting that antibody-mediated blockade of PD-L1 induces durable tumor regression and prolonged stabilization of disease in patients with advanced cancers.
5. C.Holohan, S.Van Schaeybroeck, D.B.Longley, et al. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013;13:714–726.
6. D.S.Shin, A.Ribas. The evolution of checkpoint blockade as a cancer therapy: what’s here, what’s next? Curr Opin Immunol. 2015;33:23–35.
7. N.D.Shore. Advances in the understanding of cancer immunotherapy. BJU International. 2015;116:321–329.
8. M.K.Callahan, J.D.Wolchok. At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol. 2013;94:41–53.
9. M.Bilusic, C.Heery, R.A.Madan. Immunotherapy in prostate cancer: emerging strategies against a formidable foe. Vaccine. 2011;29:6485–6497.
10. F.Ito, A.E.Chang. Cancer immunotherapy: current status and future directions. Surg Oncol Clin N Am. 2013;22:765–783. doi:10.1016/j.soc.2013.06.005.
11. M.Z.Hao, W.Y.Zhou, X.L.Du, et al. Novel anti-melanoma treatment: focus on immunotherapy. Chin J Cancer. 2014;33:458–465.
12. K.Fujita, H.Ikarashi, K.Takakuwa, et al. Prolonged disease-free period in patients with advanced epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytes. Clin Cancer Res. 1995;1:501–507.• Important study that reported significantly improved overall survival in advanced epithelial ovarian cancer by the adoptive transfer of tumor infiltrating lymphocytes after completion of adjuvant chemotherapy.
13. T.Boon, P.Van Der Bruggen. Human tumor antigens recognized by T lymphocytes. J Exp Med. 1996;183:725–729.
14. S.A.Rosenberg. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity. 1999;10:281–287.
15. R.M.Zinkernagel. Immunity against solid tumors? Int J Cancer. 2001;93(1):1–5.
16. S.A.Rosenberg. Progress in human tumour immunology and immunotherapy. Nature. 2001;411:380–384.
17. P.Yu, Y.X.Fu. Tumor-infiltrating T lymphocytes: friends or foes? Lab Invest. 2006;86:231–245. doi:10.1038/labinvest.3700389.
18. F.Klemm, J.A.Joyce. Microenvironmental regulation of therapeutic response in cancer. Trends Cell Biol. 2015;25:198–213.• Nice review paper examining recent advances in understanding the contribution of the tumor microenvironment during cancer therapy.
19. C.Devaud, L.B.John, J.A.Westwood, et al. Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy. Oncoimmunology. 2013;2:e25961. doi:10.4161/onci.25961.
20. D.M.Pardoll. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–264. doi:10.1038/nrc3239.
21. H.Nishimura, T.Okazaki, Y.Tanaka, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science. 2001;291:319–322.
22. M.E.Keir, M.J.Butte, G.J.Freeman, et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677–704.
23. H.Dong, S.E.Strome, D.R.Salomao, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8:793–800.
24. Y.Iwai, M.Ishida, Y.Tanaka, et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. 2002;99:12293–12297.
25. J.R.Brahmer, D.M.Pardoll. Immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung cancer. Cancer Immunol Res. 2013;1:85–91.
26. A.Bailey, D.F.McDermott. Immune checkpoint inhibitors as novel targets for renal cell carcinoma therapeutics. Cancer J. 2013;19:348–352. doi:10.1097/PPO.0b013e31829e3153.
27. C.U.Blank. The perspective of immunotherapy: new molecules and new mechanisms of action in immune modulation. Curr Opin Oncol. 2014;26:204–214.
28. C.U.Blank, A.Enk. Therapeutic use of anti-CTLA-4 antibodies. Int Immunol. 2015;27:3–10.
29. J.S.Weber, R.R.Kudchadkar, B.Yu, et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol. 2013;31:4311–4318.
30. O.Hamid, C.Robert, A.Daud, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369:134–144.
31. E.Sharon, H.Streicher, P.Goncalves, et al. Immune checkpoint inhibitors in clinical trials. Chin J Cancer. 2014;33:434–444. doi:10.5732/cjc.014.10122.
32. C.Kyi, M.A.Postow. Checkpoint blocking antibodies in cancer immunotherapy. FEBS Lett. 2014;588:368–376.
33. B.Boyerinas, C.Jochems, M.Fantini, et al. Antibody-dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells. Cancer Immunol Res. 2015;3:1148–1157.
34. O.S.Qureshi, Y.Zheng, K.Nakamura, et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science. 2011;332:600–603.
35. M.J.Selby, J.J.Engelhardt, M.Quigley, et al. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res. 2013;1:32–42. doi:10.1158/2326-6066.CIR-13-0013.
36. Y.F.Yang, J.P.Zou, J.Mu, et al. Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages. Cancer Res. 1997;57:4036–4041.
37. F.S.Hodi, M.Butler, D.A.Oble, et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A. 2008;105:3005–3010. doi:10.1073/pnas.0712237105.• Important study examining immunologic effects of CTLA-4 antibody blockade in previously vaccinated cancer patients and suggesting selective targeting of antitumor Tregs as a complementary strategy for combination therapy.
38. F.S.Hodi, M.C.Mihm, R.J.Soiffer, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A. 2003;100:4712–4717.
39. F.S.Hodi, S.J.O’Day, D.F.McDermott, et al Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–723.
40. C.Robert, D.Schadendorf, M.Messina, et al. Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control. Clin Cancer Res. 2013;19:2232–2239.
41. M.Maio, J.J.Grob, S.Aamdal, et al. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J Clin Oncol. 2015;33:1191–1196.
42. J.M.Reuben, B.N.Lee, C.Li, et al. Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma. Cancer. 2006;106:2437–2444.
43. A.Ribas, R.Kefford, M.A.Marshall, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol. 2013;31:616–622.
44. M.Millward, C.Underhill, S.Lobb, et al. Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours. Br J Cancer. 2013;108:1998–2004. doi:10.1038/bjc.2013.227.
45. S.Mocellin, C.Benna, P.Pilati. Coinhibitory molecules in cancer biology and therapy. Cytokine Growth Factor Rev. 2013;24:147–161. doi:10.1016/j.cytogfr.2013.01.003.
46. A.Pedoeem, I.Azoulay-Alfaguter, M.Strazza, et al. Programmed death-1 pathway in cancer and autoimmunity. Clin Immunol (Orlando, Fla). 2014;153:145–152.
47. M.J.Butte, M.E.Keir, T.B.Phamduy, et al. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity. 2007;27:111–122. doi:10.1016/j.immuni.2007.05.016.
48. D.E.Dolan, S.Gupta. PD-1 pathway inhibitors: changing the landscape of cancer immunotherapy. Cancer Control. 2014;21:231–237.
49. M.Sznol. Blockade of the B7-H1/PD-1 pathway as a basis for combination anticancer therapy. Cancer J. 2014;20:290–295. doi:10.1097/PPO.0000000000000056.
50. J.Naidoo, D.B.Page, J.D.Wolchok. Immune checkpoint blockade. Hematol Oncol Clin North Am. 2014;28:585–600. doi:10.1016/j.hoc.2014.02.002.
51. J.S.Weber, S.P.D’Angelo, D.Minor, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16:375–384. doi:10.1016/S1470-2045(15)70076-8.
52. C.Robert, G.V.Long, B.Brady, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320–330.
53. Keytruda (pembrolizumab) prescribing information. White-house Station (NJ): NMC.
54. Opdivo (nivolumab) prescribing information. Princeton (NJ): NB-MS.
55. J.Brahmer, K.L.Reckamp, P.Baas, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123–135.
56. H.Borghaei, L.Paz-Ares, L.Horn, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627–1639. doi:10.1056/NEJMoa1507643.
57. R.J.Motzer, B.Escudier, D.F.McDermott, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373:1803–1813. doi:10.1056/NEJMoa1510665.
58. C.Robert, A.Ribas, J.D.Wolchok, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384:1109–1117.
59. D.T.Le, J.N.Uram, H.Wang, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509–2520. doi:10.1056/NEJMoa1500596.
60. K.Abiko, M.Mandai, J.Hamanishi, et al. PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction. Clin Cancer Res. 2013;19:1363–1374. doi:10.1158/1078-0432.CCR-12-2199.
61. J.Hamanishi, M.Mandai, M.Iwasaki, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A. 2007;104:3360–3365.•• Landmark study reporting that the expression of PD-L1 on tumor cells and intraepithelial CD8+ T lymphocytes are independent prognostic factors in ovarian cancer.
62. M.Sznol, F.S.Hodi, D.F.Margolin, et al. Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA). 2008 ASCO Annual Meeting Vol 26 (pp 3007) (Chicago, IL) 2008.
63. B.D.Curti, M.Kovacsovics-Bankowski, N.Morris, et al. OX40 is a potent immune-stimulating target in late-stage cancer patients. Cancer Res. 2013;73:7189–7198.
64. D.A.Schaer, D.Hirschhorn-Cymerman, J.D.Wolchok. Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy. J Immunother Cancer. 2014;2:7. doi:10.1186/2051-1426-2-7.
65. N.H.Segal, A.K.Gopal, S.Bhatia, et al. A phase 1 study of PF-05082566 (anti-4-1BB) in patients with advanced cancer. J Clin Oncol. 2014;32(Suppl; abstr 3007).
66. S.L.Topalian, C.G.Drake, D.M.Pardoll. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27:450–461.
67. D.Zamarin, M.A.Postow. Immune checkpoint modulation: rational design of combination strategies. Pharmacol Ther. 2015;150:23–32.
68. M.A.Curran, W.Montalvo, H.Yagita, et al. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A. 2010;107:4275–4280.
69. K.Sakuishi, L.Apetoh, J.M.Sullivan, et al. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med. 2010;207:2187–2194. doi:10.1084/jem.20100643.
70. S.R.Woo, M.E.Turnis, M.V.Goldberg, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 2012;72:917–927.•• Important study reporting that there exists a strong synergybetween the PD-1 and LAG-3 inhibitory pathways in tolerance to both self and tumor antigens and that dual blockade of these molecules represents a promising combinatorial strategy for cancer.
71. J.D.Wolchok, H.Kluger, M.K.Callahan, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369:122–133. doi:10.1056/NEJMoa1302369.•• Landmark study demonstrating manageable safety profile and rapid tumor regression with concurrent therapy of two immune checkpoint inhibitors (nivolumab and ipilimumab) in advanced melanoma.
72. M.Sznol, H.M.Kluger, M.K.Callahan, et al. Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma. J Clin Oncol. 2014;32(Suppl):abstr LBA9003. doi:10.1200/JCO.2013.54.6911.
73. H.J.Hammers, E.R.Plimack, J.R.Infante, et al. Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2014;32(Suppl):abstr 4504.
74. S.J.Antonia, S.N.Gettinger, L.Q.Chow, et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: Interim phase I results. J Clin Oncol. 2014;32(Suppl):abstr 8023.
75. M.A.Curran, M.Kim, W.Montalvo, et al. Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production. PLoS One. 2011;6:e19499. doi:10.1371/journal.pone.0019499.
76. A.Marabelle, H.Kohrt, I.Sagiv-Barfi, et al. Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J Clin Invest. 2013;123:2447–2463.
77. Z.Guo, X.Wang, D.Cheng, et al. PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer. PLoS One. 2014;9:e89350. doi:10.1371/journal.pone.0089350.
78. H.Wei, L.Zhao, W.Li, et al. Combinatorial PD-1 blockade and CD137 activation has therapeutic efficacy in murine cancer models and synergizes with cisplatin. PLoS One. 2013;8:e84927. doi:10.1371/journal.pone.0084927.
79. L.Lu, X.Xu, B.Zhang, et al. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs. J Transl Med. 2014;12:36. doi:10.1186/1479-5876-12-36.
80. J.Larkin, V.Chiarion-Sileni, R.Gonzalez, et al Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23–34.
81. V.P.Balachandran, M.J.Cavnar, S.Zeng, et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med. 2011;17:1094–1100.
82. M.K.Callahan, G.Masters, C.A.Pratilas, et al. Paradoxical activation of T cells via augmented ERK signaling mediated by a RAF inhibitor. Cancer Immunol Res. 2014;2:70–79. doi:10.1158/2326-6066.CIR-13-0160.
83. L.J.Vella, A.Pasam, N.Dimopoulos, et al. MEK inhibition, alone or in combination with BRAF inhibition, affects multiple functions of isolated normal human lymphocytes and dendritic cells. Cancer Immunol Res. 2014;2:351–360. doi:10.1158/2326-6066.CIR-13-0181.
84. B.I.Rini, M.Stein, P.Shannon, et al. Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma. Cancer. 2011;117:758–767. doi:10.1002/cncr.25639.
85. A.Amin, E.R.Plimack, J.R.Infante, et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2014;32(Suppl):abstr 5010. doi:10.1200/JCO.2013.54.6911.
86. J.R.Westin, F.Chu, M.Zhang, et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol. 2014;15:69–77. doi:10.1016/S1470-2045(13)70551-5.
87. G.T.Motz, G.Coukos. Deciphering and reversing tumor immune suppression. Immunity. 2013;39:61–73. doi:10.1016/j.immuni.2013.07.005.
88. F.S.Hodi, D.Lawrence, C.Lezcano, et al. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res. 2014;2:632–642. doi:10.1158/2326-6066.CIR-14-0053.
89. M.Obeid, T.Panaretakis, N.Joza, et al. Calreticulin exposure is required for the immunogenicity of gamma-irradiation and UVC light-induced apoptosis. Cell Death Differ. 2007;14:1848–1850.
90. G.Kroemer, L.Zitvogel. Abscopal but desirable: the contribution of immune responses to the efficacy of radiotherapy. Oncoimmunology. 2012;1:407–408.
91. S.R.Gameiro, M.L.Jammeh, M.M.Wattenberg, et al. Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing. Oncotarget. 2014;5:403–416. doi:10.18632/oncotarget.1719.
92. S.Demaria, N.Kawashima, A.M.Yang, et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res. 2005;11:728–734.
93. L.Deng, H.Liang, B.Burnette, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014;124:687–695.• Important study that provides evidence for a close interaction between ionizing radiation, T-cells, and the PD-L1/PD-1 axis, establishing a basis for the rational design of combination therapy with immune modulators and radiotherapy.
94. S.M.Hiniker, D.S.Chen, S.Reddy, et al. A systemic complete response of metastatic melanoma to local radiation and immunotherapy. Transl Oncol. 2012;5:404–407.
95. M.A.Postow, M.K.Callahan, C.A.Barker, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366:925–931. doi:10.1056/NEJMoa1112824.
96. E.B.Golden, S.Demaria, P.B.Schiff, et al. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol Res. 2013;1:365–372.
97. R.J.Sullivan, D.P.Lawrence, J.A.Wargo, et al. Case records of the Massachusetts General Hospital. Case 21-2013. A 68-year-old man with metastatic melanoma. N Engl J Med. 2013;369:173–183. doi:10.1056/NEJMcpc1302332.
98. S.F.Slovin, C.S.Higano, O.Hamid, et al. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann Oncol. 2013;24:1813–1821.
99. A.Tesniere, L.Apetoh, F.Ghiringhelli, et al. Immunogenic cancer cell death: a key-lock paradigm. Curr Opin Immunol. 2008;20:504–511.
100. L.Zitvogel, O.Kepp, G.Kroemer. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol. 2011;8:151–160. doi:10.1038/nrclinonc.2010.223.
101. L.Zitvogel, L.Galluzzi, M.J.Smyth, et al. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity. 2013;39:74–88.
102. C.Robert, L.Thomas, I.Bondarenko, et al Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517–2526.
103. T.J.Lynch, I.Bondarenko, A.Luft, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol. 2012;30:2046–2054. doi:10.1200/JCO.2011.38.4032.
104. M.Reck, I.Bondarenko, A.Luft, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol. 2013;24:75–83.
105. S.J.Antonia, J.R.Brahmer, S.N.Gettinger, et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2014;32(Suppl):abstr 8113. doi:10.1200/JCO.2013.54.6911.
106. R.H.Vonderheide, J.M.Burg, R.Mick, et al. Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors. Oncoimmunology. 2013;2:e23033. doi:10.4161/onci.23033.
107. A.A.Hurwitz, T.F.Yu, D.R.Leach, et al. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc Natl Acad Sci U S A. 1998;95:10067–10071.
108. A.van Elsas, A.A.Hurwitz, J.P.Allison. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med. 1999;190:355–366.
109. P.Sabbatini, T.Tsuji, L.Ferran, et al. Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clin Cancer Res. 2012;18:6497–6508. doi:10.1158/1078-0432.CCR-12-2189.
110. K.Sanderson, R.Scotland, P.Lee, et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol. 2005;23:741–750.
111. C.H.Son, J.H.Bae, D.Y.Shin, et al. CTLA-4 blockade enhances antitumor immunity of intratumoral injection of immature dendritic cells into irradiated tumor in a mouse colon cancer model. J Immunother. 2014;37:1–7.
112. J.Espenschied, J.Lamont, J.Longmate, et al. CTLA-4 blockade enhances the therapeutic effect of an attenuated poxvirus vaccine targeting p53 in an established murine tumor model. J Immunol. 2003;170:3401–3407.
113. M.Chakraborty, J.Schlom, J.W.Hodge. The combined activation of positive costimulatory signals with modulation of a negative costimulatory signal for the enhancement of vaccine-mediated T-cell responses. Cancer Immunol Immunother. 2007;56:1471–1484. doi:10.1007/s00262-007-0291-6.
114. J.D.Wolchok, A.Hoos, S.O’Day, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15:7412–7420.• Landmark study evaluating the novel immune therapy response criteria using data from ipilimumab phase II clinical trials in patients with advanced melanoma.
115. E.A.Eisenhauer, P.Therasse, J.Bogaerts, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–247.
116. Y.C.Kong, W.Z.Wei, Y.Tomer. Opportunistic autoimmune disorders: from immunotherapy to immune dysregulation. Ann N Y Acad Sci. 2010;1183:222–236.
117. C.Robert, J.C.Soria, A.M.Eggermont. Drug of the year: programmed death-1 receptor/programmed death-1 ligand-1 receptor monoclonal antibodies. Eur J Cancer. 2013;49:2968–2971. doi:10.1016/j.ejca.2013.07.001.
118. L.Gelao, C.Criscitiello, A.Esposito, et al. Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an “innocent bystander”. Toxins. 2014;6:914–933.
119. M.A.Postow. Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book. 2015;35:76–83. doi:10.14694/EdBook_AM.2015.35.76.
120. J.S.Weber, J.C.Yang, M.B.Atkins, et al. Toxicities of immunotherapy for the practitioner. J Clin Oncol. 2015;33:2092–2099.